B, D., X, W., W, F., Z, W., J, G., W, Z., . . . S, G. (2011). Anti-DR5 monoclonal antibody-mediated DTIC-loaded nanoparticles combining chemotherapy and immunotherapy for malignant melanoma: Target formulation development and in vitro anticancer activity. Dove Medical Press.
Cita Chicago Style (17a ed.)B, Ding, et al. Anti-DR5 Monoclonal Antibody-mediated DTIC-loaded Nanoparticles Combining Chemotherapy and Immunotherapy for Malignant Melanoma: Target Formulation Development and in Vitro Anticancer Activity. Dove Medical Press, 2011.
Cita MLA (8a ed.)B, Ding, et al. Anti-DR5 Monoclonal Antibody-mediated DTIC-loaded Nanoparticles Combining Chemotherapy and Immunotherapy for Malignant Melanoma: Target Formulation Development and in Vitro Anticancer Activity. Dove Medical Press, 2011.